The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab
NCT ID: NCT07052877
Last Updated: 2025-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
20 participants
OBSERVATIONAL
2025-07-31
2027-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma
NCT01939574
Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.
NCT03225963
Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor
NCT02784054
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
NCT02287428
Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma
NCT02782754
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with glioblastoma receiving Bevacizumab as part of their standard of care
PSMA PET/CT scan
PSMA PET scan will be used to monitor changes in PSMA expression in response to bevacizumab.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PSMA PET/CT scan
PSMA PET scan will be used to monitor changes in PSMA expression in response to bevacizumab.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG 0-2
* Able to provide informed consent for the study
* Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour
* Confirmed glioblastoma IDH1/2 wildtype (WHO2021)
* For bevacizumab treatment as per treating physician
* Able to comply with trial requirements
Exclusion Criteria
* Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope
* Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging
* Does not fulfill PBS requirements for bevacizumab
* Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Royal North Shore Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alexander Yuile
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GUAVA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.